LUTRATE Trademark

Trademark Overview

On Thursday, October 22, 2020, a trademark application was filed for LUTRATE with the United States Patent and Trademark Office. The USPTO has given the LUTRATE trademark a serial number of 79301389. The federal status of this trademark filing is REGISTERED as of Tuesday, October 19, 2021. This trademark is owned by GP Pharm S.A.. The LUTRATE trademark is filed in the Pharmaceutical Products category with the following description:

Anti-cancer pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer
lutrate

General Information

Serial Number79301389
Word MarkLUTRATE
Filing DateThursday, October 22, 2020
Status700 - REGISTERED
Status DateTuesday, October 19, 2021
Registration Number6522700
Registration DateTuesday, October 19, 2021
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 3, 2021

Trademark Statements

Goods and ServicesAnti-cancer pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, January 12, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGP Pharm S.A.
Party Type30 - Original Registrant
Legal Entity Type85 - NOT AVAILABLE
AddressES
Party NameGP Pharm S.A.
Party Type20 - Owner at Publication
Legal Entity Type85 - NOT AVAILABLE
AddressES
Party NameGP Pharm S.A.
Party Type10 - Original Applicant
Legal Entity Type85 - NOT AVAILABLE
AddressES

Trademark Events

Event DateEvent Description
Sunday, April 24, 2022FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, April 1, 2022FINAL DISPOSITION NOTICE SENT TO IB
Friday, April 1, 2022FINAL DISPOSITION PROCESSED
Wednesday, January 19, 2022FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, October 19, 2021REGISTERED-PRINCIPAL REGISTER
Saturday, August 21, 2021NOTIFICATION PROCESSED BY IB
Tuesday, August 3, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 3, 2021PUBLISHED FOR OPPOSITION
Wednesday, July 28, 2021NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, July 28, 2021NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, July 14, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, June 25, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, June 21, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, June 21, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, June 21, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, April 18, 2021REFUSAL PROCESSED BY IB
Monday, March 29, 2021NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Monday, March 29, 2021REFUSAL PROCESSED BY MPU
Thursday, March 25, 2021NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, March 24, 2021NON-FINAL ACTION WRITTEN
Wednesday, March 24, 2021PREVIOUS ALLOWANCE COUNT WITHDRAWN
Wednesday, March 24, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, March 23, 2021ASSIGNED TO EXAMINER
Saturday, January 16, 2021APPLICATION FILING RECEIPT MAILED
Tuesday, January 12, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, January 11, 2021LIMITATION FROM ORIGINAL APPLICATION ENTERED
Friday, January 1, 2021SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB

Related Keywords

lutrate preparations pharmaceutical cancer treatment anti